PureTech Health plc reported a leadership change, announcing that Robert Lyne has been appointed as its Chief Executive Officer. This update comes through a Form 6-K submission that notes the company issued a press release titled “PureTech Appoints Robert Lyne as Chief Executive Officer” on December 18, 2025. The press release is furnished as Exhibit 99.1 and incorporated by reference, indicating it contains further details about Lyne’s new role and the company’s leadership plans.
PureTech Health plc submitted a Form 6-K as a foreign private issuer to provide investors with its half-year information package. The company furnished a press release summarizing its half-year report, an interim management report and financial review for the six months ended June 30, 2025 and 2024, and unaudited condensed consolidated financial statements covering the same periods and as of December 31, 2024. These materials give a detailed update on the company’s mid-year performance and financial position, but the specific financial results are contained in the attached exhibits rather than in this cover document.
Citigroup and several of its subsidiaries report a collective beneficial ownership of 13,220,374 ordinary shares of PureTech Health plc, representing 5.5% of the class. The filing names five Citigroup reporting persons and discloses that the position carries shared voting power and shared dispositive power; no sole voting or dispositive authority is reported.
The statement indicates the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The filing also describes the chain of ownership among the Citigroup entities that hold the position.